SEARCH

SEARCH BY CITATION

References

  • 1
    Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
  • 2
    Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Nyberg SL et al. Overcoming a positive crossmatch in living donor kidney transplantation. Am J Transplant 2003; 3: 1017.
  • 3
    Schweitzer EJ, Wilson JS, Fernandez-Vina M, Fox M, Gutierrez M, Willand A et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 1531.
  • 4
    Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
  • 5
    Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulin. Am J Transplant 2002; 2: 758.
  • 6
    Tyan D, Li V, Czer L, Trento A, Jordan S. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553.
  • 7
    Bearden CM, Agarwal A, Book BK et al. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. Human Immunol 2004; 65: 803809.
  • 8
    Gloor JM, DeGoey S, Ploeger N, Gebel H, Bray R, Moore SB et al. Persistence of low levels of alloantibody after desensitization in crossmatch positive living donor kidney transplantation. Transplantation 2003; 78: 221.
  • 9
    Winters JL, Gloor JM, Pineda AA, Stegall MD, Moore SB. Plasma exchange conditioning for ABO-incompatible kidney transplantation. J Clin Apheresis 2004; 19: 1.
  • 10
    Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM et al. Antibody-mediated rejection criteria- an addition to the Banff '97 classification of renal allograft rejection. Am JTransplant 2003; 3: 708.
  • 11
    Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D et al. Specific and durable elimination of antibody to donor HLA antigens in renal transplant patients. Transplantation 2003; 76: 1519.
  • 12
    Salama AD, Delikouras A, Pusey CD, Cook HT, Bhangal G, Lechler RI et al. Transplant accomodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260.
  • 13
    Jordan SC, Tyan D, Stablein DM, McIntosh M, Vo A. Evaluation of intravenous immunoglobulin (IVIG) as an agent to lower allosensitization and improve transplantation in highly-sensitized adult ESRD patients: report of the NIH IG02 trial. Am J Transplant 2003; 3(Suppl. 5): 551.
  • 14
    Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542.